MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
3.730
+0.040
+1.08%
Closed 19:38 05/06 EDT
OPEN
3.750
PREV CLOSE
3.690
HIGH
3.790
LOW
3.600
VOLUME
213.36K
TURNOVER
0
52 WEEK HIGH
9.77
52 WEEK LOW
0.1700
MARKET CAP
82.87M
P/E (TTM)
-1.9498
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TPST last week (0429-0503)?
Weekly Report · 1d ago
Weekly Report: what happened at TPST last week (0422-0426)?
Weekly Report · 04/29 12:01
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Therapeutics, Inc. Is a clinical-stage biotechnology company developing first-in-class targeted and immune-mediated therapeutics to fight cancer. The company granted one employee nonqualified stock options to purchase an aggregate of 5,400 shares of its common stock.
Barchart · 04/26 15:05
Weekly Report: what happened at TPST last week (0415-0419)?
Weekly Report · 04/22 11:48
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch
Seeking Alpha · 04/17 17:26
BUZZ-U.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
The Nasdaq and the S&P 500 were muted on Tuesday as higher Treasury yields pressured equities. The blue-chip Dow bucked the trend on robust results from health insurance heavyweight UnitedHealth. The Dow Jones Industrial Average was up 0.13% at 37,783.35. UnitedHealth Group's quarterly results beat expectations.
Reuters · 04/16 17:52
BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals
Dow Jones Industrial Average up 0.13% after upbeat results from health insurer UnitedHealth. Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals among top stocks on the move. Higher Treasury yields and conflict in the Middle East keep investors on edge.
Reuters · 04/16 15:39
BUZZ-U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene
The Dow Jones Industrial Average was down 0.45% on Monday. Goldman Sachs boosted by robust gains. Snap One, Encore Wire, Centene were among the top stocks on the NYSE. The S&P 500 and Nasdaq Composite both fell on the day. U.S. Retail sales were stronger than expected.
Reuters · 04/15 17:48
More
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Webull offers Tempest Therapeutics Inc stock information, including NASDAQ: TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.